TAP Pharmaceutical Products Company Description
TAP Pharmaceutical Products has tapped into hot drug industry trends. The joint venture between Abbott Laboratories and Takeda Pharmaceutical Company develops and sells drugs in the US and Canada. The company's products target therapeutic areas such as cancer, gastroenterology, gynecology, and urology. The company markets Prevacid, which is used to treat acid reflux disease and ulcers. Its Lupron (and sustained released formula Lupron Depot) treat advanced prostate cancer, but can also treat endometriosis in women and central precocious puberty in children. Parents Takeda and Abbott Labs announced plans in 2008 to split up the joint venture, which has been in existence since 1977.
View the Comprehensive Company Description for TAP Pharmaceutical Products
The Company Description provides a historical perspective of TAP Pharmaceutical Products's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of TAP Pharmaceutical Products's evolution in the marketplace.
